key: cord-0277941-cv46h9cc
authors: Zhang, Lanxin; Wang, Junyu; von Kleist, Max
title: Numerical approaches for the rapid analysis of prophylactic efficacy against HIV with arbitrary drug-dosing schemes
date: 2021-07-22
journal: bioRxiv
DOI: 10.1101/2021.07.22.453374
sha: eebf2f0cf5ac0f617df04a9781533f186be0348e
doc_id: 277941
cord_uid: cv46h9cc

Pre-exposure prophylaxis (PrEP) is an important pillar to prevent HIV transmission. Because of experimental and clinical shortcomings, mathematical models that integrate pharmacological, viral- and host factors are frequently used to quantify clinical efficacy of PrEP. Stochastic simulations of these models provides sample statistics from which the clinical efficacy is approximated. However, many stochastic simulations are needed to reduce the associated sampling error. To remedy the shortcomings of stochastic simulation, we developed three numerical methods that allow predicting the efficacy of arbitrary prophylactic regimen directly from a viral dynamics model, without sampling. We apply the methods to various hypothetical dolutegravir (DTG) prophylaxis scenarios. The approaches are verified against one another, as well as state-of-the-art stochastic simulation. While the methods are more accurate than stochastic simulation, they are superior in terms of computational performance. For example, a continuous 6-month prophylactic profile is computed within a few seconds on a laptop computer. The methods’ computational performance, therefore, substantially expands the horizon of feasible analysis in the context of PrEP, and possibly other applications. Author summary Pre-exposure prophylaxis (PrEP) is an important tool to prevent HIV transmission. However, experimental identification of parameters that determine prophylactic efficacy is extremely difficult. Clues about these parameters could prove essential for the design of next-generation PrEP compounds. Integrative mathematical models can fill this void: Based on stochastic simulation, a sample statistic can be generated, from which the prophylactic efficacy is estimated. However, for this sample statistic to be accurate, many simulations need to be performed. Here, we introduce three numerical methods to directly compute the prophylactic efficacy from a viral dynamics model, without the need for sampling. Based on several examples with dolutegravir (DTG) -based short- and long-term PrEP, as well as post-exposure prophylaxis we demonstrate the correctness of the new methods and their outstanding computational performance. Due to the methods’ computational performance, a number of analysis, including formal sensitivity analysis are becoming feasible with the proposed methods.

Since its transfer to human in the early 20th century [1] , HIV remains a major public 2 health treat. According to UNAIDS estimates, approximately 38 million individuals 3 worldwide are infected with the human immunodeficiency virus (HIV) [2] . HIV 4 continues to spread and the latest incidence estimates amount to about 1.7 million new 5 infections in 2019 [2] . Sub-Saharan Africa is hit hardest by the HIV pandemic, and due 6 to COVID many services, including HIV control and treatment, had been suspended, 7 which could lead to a long-term re-surge in infections [3] . 8 Nowadays, about 30 antiviral compounds are available that can stop HIV replication 9 and prevent the acquired immunodeficiency symdrome (AIDS) and AIDS-related 10 death [4] . However, unlike many other infections, no cure is available to clear HIV, 11 which can persist in latent reservoirs for decades [5, 6] . Available treatments therefore 12 have to be taken life-long to prevent the relapse of virus from latent reservoirs and to 13 prevent AIDS. As a consequence, much focus around fighting HIV turned towards HIV 14 prevention. While a vaccine would be the ideal tool for the purpose, intrinsic difficulties 15 have so far precluded the development of an effective vaccine against HIV [7] . However, 16 based on the successes in antiviral drug discovery, recent years have seen an increasing 17 interest in utilising antivirals not only for treatment, but also to prevent HIV 18 transmission. Two general strategies are currently implemented for this purpose: (i) 19 Treatment-as-prevention (TasP) intends to put individuals with an HIV diagnosis 20 immediately on treatment, which essentially makes them non-contagious by decreasing 21 the number of viruses they can expose to uninfected individuals [8] . (ii) Pre-exposure 22 prophylaxis (PrEP) on the other hand prevents establishment of HIV infection after 23 exposure [9, 10] . 24 Currently, two oral PrEP options, the patent-expired two-compound combination 25 Truvada, as well as the patent-protected two-compound combination Descovy are 26 available. However, many more drugs are investigated for re-purposing [11, 12] , or under 27 de novo development [13] , including topically-applied drugs, long-acting injectibles, as 28 well as drug eluting implants [14] [15] . 29 However, demonstrating clinical efficacy of novel PrEP compounds constitutes a 30 formidable task. Clinical efficacy of PrEP is understood as the reduction in the number 31 of infected individuals in a treatment-vs. a control arm of a clinical trial [9] . A major 32 statistical problem arises from the fact that HIV transmission probabilities are 33 extremely low (e.g. < 3% during unprotected sex [16] ; far less for condom-or PrEP 34 usage, and when potential transmitters take antiviral therapy). Hence, the number of 35 evaluable data points (= infected individuals in a trial treatment and control arm) are 36 extremely low and prone to chance events. Since the approval of Truvada-based PrEP, 37 novel PrEP interventions have to be compared with Truvada, worsening the statistical how drug dosing may alter the risk of acquiring HIV infection, depending on its timing 53 and the magnitude of viral exposure. 54 A key feature of HIV biology is that transmission is highly inefficient. For example, 55 < 3% of unprotected sex acts between sero-discordant partners result in HIV 56 infection [16] . Moreover, the number of genetically distinct founder viruses is extremely 57 low [19] . This argues that stochastic processes play an important role during early 58 infection, and that, in the majority of exposures, the virus becomes eliminated before it 59 irreversibly infects the new host. Therefore, stochastic modelling and simulation 60 approaches are used to estimate the efficacy of PrEP by integrating various host-, viral-61 and drug-specific parameters. For fixed drug concentrations, Monte-Carlo schemes, 62 analytical, as well as probability generating ODE systems have been developed [20] [21] [22] . 63 These approaches have been extended to include time-varying drug concentrations by 64 integrating pharmacokinetic characteristics, as well as realistic dosing schemes, but were 65 restricted to particular drugs, drug classes or prophylactic schemes [23, 24] . Recently, a 66 numerically exact Monte-Carlo approach was introduced that can be universally applied 67 to study the effects of dosing, pharmacokinetics, drug adherence, timing and extend of 68 viral exposure on the risk of HIV infection [11, 12] . Despite its advantage, the 69 introduced stochastic simulation approach is still computationally prohibitive, in a sense 70 that it would not allow to compute a PrEP efficacy from a history of drug dosing 'on 71 the fly', e.g. to be useful in a health app or computer program that empowers PrEP 72 users, akin to [25] . 73 In this work, we derive three numerical methods from an established viral dynamics 74 model of HIV infection [26, 27] that overcome aforementioned limitations. These 75 methods estimate the probability of viral extinction using a set of low-dimensional 76 deterministic Ansatz functions that are either solved iteratively or with standard 77 numerical solvers. The fastest of the three methods allows to quantify PrEP efficacy 78 within fractions of a second on a standard computer and is numerically exact up to the 79 tolerance level of an ODE-solver. All developed methods fully integrate drug 80 pharmacokinetics, which allows to estimate the influence of drug dosing, drug 81 adherence, timing and magnitude of viral exposure on PrEP efficacy. 82 We illustrate the methods with the second-generation integrase inhibitor 83 dolutegravir (DTG). Taking advantage of the outstanding performance of the developed 84 methods, we presented several show cases to display their possible applications: By 85 estimating (i) both pre-and post-exposure prophylaxis with different dosing of the drug, 86 as well as timing-and extent of virus exposure, (ii) prophylactic protection profiles over 87 a 6 month dosing history, as well as (iii) timing-and probability of viral establishment 88 with different exposures.

Below, we will introduce a within-host HIV dynamics model, as well as a 91 pharmacokinetic-pharmacodynamic model of the second-generation integrase 92 dolutegravir, which serve as a common basis to derive and demonstrate the presented 93 numerical methods to compute HIV prophylactic efficacy. We will then introduce the HIV viral dynamics model 103 We adapted the viral dynamics model from [26, 27] . We use this model, because it allows 104 to mechanistically integrate the mechanisms of action of all approved drugs (and drug 105 classes) [26] and because it allows to integrate both drug-specific in vitro and in vivo 106 parameters [24] . In its most basic form, the considered viral replication cycle consists of 107 free infectious viruses V, early infected T-cells (T 1 ), and productively infected T-cells 108 (T 2 ). The dynamics can be defined by six reactions R 1 to R 6 with propensities a 1−6 :

where we assume that the integrase inhibitor dolutegravir (DTG) inhibits proviral 110 genome integration (reaction R 5 ), with details outlined below. Moreover, we assume 111 that a T 2 -cell continuously produces viruses (with reaction rate R 6 ) until it is cleared Table 1 . Schematic of the utilized viral dynamics model. V, T 1 , T 2 denote virus, early infected T-cells and productively infected T-cells respectively. Each reaction is denoted by its reaction propensity a 1 − a 6 . Briefly, a free virus can either be cleared (with reaction propensity a 1 ), or infect a susceptible T cell with rate a 4 to yield an early infected cell T 1 . These cells denote a state where the virus has penetrated the host cell, but has not yet integrated its proviral DNA into the host cell's genome, thus not yet producing viral offspring. Early infected cell T 1 can either be cleared with rate a 2 or the proviral DNA irreversibly become integrated into the host cells DNA with rate a 5 to yield a productively infected T-cell T 2 . T 2 cells start producing infectious progeny virus with rate a 6 , or they may get cleared by the immune system with rate a 3 .

115 Dolutegravir (DTG) is a second-generation integrase inhibitor which may potentially be 116 used as prophylaxis against HIV. Moreover, we study it because of its similarity to 117 carbotegravir, which is in clinical development as a next-generation PrEP compound.

To evaluate the PrEP utility of DTG, we utilize a previously developed 119 pharmacokinetic-pharmacodynamic model of the drug [11] . We utilize the non-linear mixed effects pharmacokinetic model introduced in [11] . In Individual parameters for a population of HIV-negative individuals were sampled from 125 the distributions defined in [11] (Table 2 therein). The structural pharmacokinetic 126 model is given by the following set of ordinary differential equations (ODEs):

where Z 1 represents the amount of drug in the dosing compartment, and Z 3 denotes the 130 DTG concentration in the peripheral compartment. D = Z 2 is the DTG concentration 131 in the blood plasma, i.e. the value of interest. In a therapy, the value Z 1 increases 132 whenever a dosing event τ k occurs: Z 1,t = Z 1,t + dose k .

Since DTG is an integrase inhibitor, it acts intracellularly by preventing the integration 135 of viral DNA. This effect can be translated into a decrease in propensity function a 5 by 136

where η D (t) denotes the direct effect of DTG at time t, which is modelled using the 138 Emax-equation [37] :

where D t is the drug concentration in the blood plasma at time t. IC 50 represents the 140 plasma drug concentration by which the activity of proviral integration is inhibited by 141 50%, and m denotes a hill coefficient. In this work IC 50 = 89 [nM] and m = 1.3 is used, 142 which are values after protein adjustment [38] (free drug hypothesis).

The prophylactic efficacy ϕ is defined as the reduction of infection risk for a prophylactic 145 regimen S, compared to the infection probability in the absence of prophylaxis:

where P I (Y t , S) and P I (Y t , ∅) denote the infection probabilities in the presence and 147 absence of a prophylactic regimen S for a given virus state (e.g. exposure) Y t at time t. 148 We consider a prophylactic regimen to be a continuous function of drug concentrations. 149 The state of the viral compartments Y t is defined as Y t = [V, T 1 , T 2 ] T , where V , T 1 and 150 T 2 are the numbers of viruses, T 1 -cells and T 2 -cells, respectively. For the absence of 151 prophylaxis, P I (Y t , ∅), analytical solutions have been presented in [38] . For a 152 prophylactic regimen S they need to be determined numerically.

The infection probability is the complement of the extinction probability P E . We 154 thus have

where

In words, the probability that all viral compartments will eventually go extinct, starting 156 from state Y t at time t. Under the reasonable assumption of statistical independence, 157 akin to [38] , we can define the extinction probability as:

whereV ,T 1 ,T 2 represent the unit vectors:

Thus, if P E (V , S), P E (T 1 , S) and P E (T 2 , S) can be determined, the prophylactic 160 efficacy can also be calculated using eq (12)- (14) , 161 Low-dimensional deterministic Ansatz functions 162 In this section, we present three methods to compute the extinction probability for the 163 unit vectors P E (V , S), P E (T 1 , S) and P E (T 2 , S), which enable the integration of 164 arbitrary pharmacokinetic profiles resulting from some prophylactic regimen S. As The viral dynamic model illustrated in Fig. 1 is interpreted as a continuous time, discrete state Markov process [39] . Therefore, the time when a particular state transition happens is exponentially distributed according to the reaction propensities.

In the viral replication cycle, if the initial state is Y 0 = [1, 0, 0] T , there are two possible next states: (i) the virus is cleared Y τ = [0, 0, 0] T , or a T 1 -cell emerges Y τ = [0, 1, 0] T ,

where τ is a random, exponentially distributed waiting time, until a reaction fires. The probability density function (PDF) for state transition V → T 1 can be derived as:

where F a1 (x) is the cumulative probability of state transition V → ∅ between time point 0 and x, and f a4 (x) is the probability density function for transition V → T 1 . In words: The probability that V → T 1 occurs and V → ∅ has not occurred yet. Corresponding derivations hold for the process T 2 → T 2 + V:

For the process T 1 → T 2 , the probability distribution f a5 (x) is different since the values 169 of a 5 are time-dependent when an integrase inhibitor is applied (as in our example) that 170 affects the reaction according to its pharmacokinetic-pharmacodynamic (PK-PD) 171 properties and its dosing history. Using a Taylor approximation, the probability 172 distribution for f T1→T2 (x) can be derived as (Supplementary Text S1):

The precondition for the NTM method is that the concentration-time profile of the 175 prophylactic regimen S must be known in advance. This can be achieved by solving the 176 deterministic pharmacokinetic equations (7)-(9) for a particular dosing schedule using 177 standard ODE-solvers. Given these pharmacokinetic profiles, the NTM method delivers 178 an extinction probability-time profile. Mathematically, the method calculates P E (Y t , S). 179

Now, we can compute P E Y t =V , S to denote the extinction probability of unit 180 vectorV , i.e. the probability that a single virus that exists at time t will be cleared in 181 the future. The other two values of interest, which will be outlined further below, are 182 the extinction probability for a T 1 cell and for a T 2 cell, P E Y t =T 1 , S and 183 P E Y t =T 2 , S , respectively. For brevity, we will skip S in the notations, keeping in 184 mind that everything refers to a prophylactic strategy with some underlying PK-PD 185 profile that affects reaction rate a 5 in a time-dependent manner.

The extinction probability of one virus at time t, i.e. P E Y t =V , consists of two 187 parts: the probability of direct extinction, with the value a1 a1+a4 ; and the probability 188 that virus is first transformed to T 1 , and eventually gets cleared. Since we already know 189 the probability distribution of state transition V → T 1 , we can split the time into small 190 steps so that the probability of V → T 1 can be accurately approximated for each time 191 step. We then get (detailed derivation in Supplementary Text S1):

where ∆t is a sufficiently small time step and i denotes the number of steps beginning 193 from time point t. The variable d 1 (t, i) is a function that represents the probability that 194

the state transition V → T 1 occurs within the ith time step, i.e.

and is given further below.

196 P E Y t =T 2 is calculated analogously:

where d 3 (t, i) denotes the probability that the state transition T 2 → V + T 2 occurs 198 within the ith time step. In the equation above, we assumed statistical 199 independence [38] , such that

Since the value of a 5 varies over time, the first term in P E Y t =T 1 is derived in a 202 more general way (Supplementary Text S1):

where the first term is the complement probability of transition T 1 → T 2 occurring 204 some time after t.

The probability functions d 1 (t, i), d 2 (t, i), d 3 (t, i) for the respective state transitions can be computed based on eq (16)-(18) as outlined in Supplementary Text S1.

The set of equation for this method is given by eqs (19)- (22) . This method is solved 206 iteratively backwards using dynamic programming, as exemplified in the pseudocode 207 given in Supplementary Text S2.

This method has foundations in the embedded Markov Chain, focusing on all possible 209 one-step state transitions and their corresponding probability. To simulate the 210 time-dependent probabilities of state transition, we performed a time-discretization into 211 sufficiently small steps ∆t. Here, we assumed that the extinction probabilities stay 212 approximately unchanged inside each step (we make a zero-order Taylor approximation 213 to compute d 2 (t, i)), as outlined in the derivation in Supplementary Text S1. Of course, 214 higher-order approximations can also be used. If the time-discretization is omitted 215 altogether, we derive the third method (PGS) as outlined in Supplementary Text S6. we can compute the extinction probabilities for e.g. stateV at time point t as follows:

with the following interpretations:

is the probability that a T 1 -cell that exists at time t + ∆t will eventually be eliminated. Finally, the probability that no state transition occurs in [t, t + ∆t) is given by

The terms P Y t+∆t = 0 | Y t =V and P Y t+∆t =T 1 | Y t =V can be derived based on the calculations for the distribution of state transition events, as outlined in Supplementary Text S1. Using these derivations, the the final expression for

Similarly, for P E Y t =T 1 we get:

and for P E Y t =T 2 :

Similar to the next transition method (NTM), when implementing the constant time 222 step method, we make a zero-order Taylor approximation to a 5 (s) as visible in eq (25) 223 and assumed that all extinction probabilities P E stay unchanged for each time step In the CTSM, we constructed a discrete-time Markov Chain for time steps ∆t and approximated a 5 (s) within such a time-step s ∈ [t, t + ∆t) using a zero-order Taylor approximation, i.e. a 5 (s) ≈ a 5 (t). Because of this approximation, the precision of the method depends on ∆t. On the contrary, for the PGS we will take ∆t → 0 to derive a set of continuous Ansatz functions. With this idea in mind, we differentiate eqs. (24)- (26) to derive the following set of ordinary differential equations (Supplementary Text S1):

Given a 5 (t) and initial values, equations above can be solved by any ODE solver, as T e + τ , we initialize the extinction probabilities with the values in the absence of drugs, 247 e.g. P E (Y Te =V , S) = P E (V , ∅), P E (Y Te =T 1 , S) = P E (T 1 , ∅) and 248 P E (Y Te =T 2 , S) = P E (T 2 , ∅), which can be determined analytically [38] . Probability generating system (PGS). The PGS does not require to pre-define 255 a time-step (this is done by the ODE solver). Like with the other methods, the 256 simulation time horizon is extended analogously and the extinction probabilities are 257 initiated with the values in the absence of drugs. We use solve ivp in SciPy [40] with 258 the LSODA solver (linear multistep method) and default settings to solve the system of 259 ODEs backwards in time.

EXTRANDE. We implemented the exact stochastic simulation method 261 EXTRANDE with configurations identical to [11] . 

with {t i }, i = 1, . . . , n denotes a set of n viral exposures and

due to statistical independence, where P E (Y ti ) is computed as described above.

If n viral exposures occur at the same time t i = t, we have

To assess the validity of this assumption we also simulated multiple viral challenges with 282 EXTRANDE and compared the results.

Computation of density function of the extinction event 284 So far, we computed the probability that viral extinction is eventually happening after 285 viral exposure at some time t; P E Y t =V , S . I.e., we only care if extinction 286 eventually occurs, regardless of when it happens.

The introduced methods can however also be used to estimate the probability that 288 the extinction occurs in a specific time range. To solve for this probability, we can e.g. 289 alter the initial conditions of the PGS. In essence, we are interested in the extinction 

Efficacy of PrEP-on-demand with DTG 310 Using the three proposed methods, we computed the time course of the extinction 311 probability P E (Y t , S) and the corresponding prophylactic efficacy ϕ(Y t , S) for a 3-days 312 once daily short-course oral 50mg DTG prophylaxis, that was either initiated shortly 313 after viral exposure (post-exposure prophylaxis, PEP) or before virus exposure 314 (pre-exposure prophylaxis, PrEP). Fig. 2A shows the profiles of the extinction 315 probability and Fig. 2B depicts the corresponding prophylactic efficacy. In Figure 2 , for 316 illustration, we depict these quantities for Y t =V , Y t =T 1 and Y t =T 2 individually.

From these quantities, the extinction probability for an arbitrary initial state can be 318 calculated based on eq (14) . All three proposed methods yielded indistinguishable 319 results. In the figure we therefore only display the results of the PGS. Fig. 2A & B) is placed on the time axis and the methods are backwards propagated to 323 some time before the first dose of the drug was given. Any time points before the first 324 dose denote PEP, whereas PrEP refers to time points after the first dose of the drug.

For example, the value of the red line in Fig. 2B at t = −2 (days) indicates that the 326 efficacy of a 3 days 50mg oral DTG post-exposure prophylaxis, that was initiated 2 days 327 after exposure to a single virus particle, is about 35%. If exposure occurred at t = 0 328 (coinciding with the first drug intake), the efficacy would be ≈ 90%. As described above, 329 the new methods therefore compute a prophylactic efficacy profile for a time span of 330 interest, i.e. every point on this time-efficacy curve represents the prophylactic efficacy 331 ϕ(Y t , S t0 ) conditioned that the viral exposure occurred at the indicated time point and 332 the prophylactic regimen S was started at t 0 = 0.

From a biological point of view, Figure 2B nicely highlights the role of the molecular 334 target of the integrase inhibitor DTG within the viral replication cycle [38] : The drug is 335 able to potently prevent infection if it emanates from a virus V or a T 1 cell 336 (compartments proceeding its molecular target process), but not from a T 2 (a 337 compartment succeeding its molecular target process).

While the three proposed methods yielded indistinguishable results for the presented 339 July 6, 2021 (Fig. 2) , their run times were markedly different, Table 2 : While NTM 340 required about three minutes on a AMD R5 core with 3.6 Ghz and 16 GB RAM, CTSM 341 only needed 5.9 seconds and PGS ran in a fraction of a second. Notably, if stochastic 342 simulation was performed (as in [11] ), several thousand stochastic samples need to be 343 generated to approximate the prophylactic efficacy ϕ(Y t , S) from the sample statistic 344 for a single time point t. Run time to compute the prophylactic profiles in Fig. 2 on an single AMD R5 core with 3.6 Ghz and 16 GB RAM.

Comparison with stochastic simulation (EXTRANDE) 346 Previously, an exact hybrid stochastic simulation method called EXTRANDE was 347 introduced in [41] . We subsequently adapted the algorithm to estimate PrEP efficacy 348 against HIV [11, 12] . Here, we used EXTRANDE to verify the accuracy of the proposed 349 methods. Fig. 3 shows the predicted efficacy of a three days prophylaxis with either 2 or 350 50mg oral DTG started at t = 0 using EXTRANDE vs. the proposed methods. In (Table 2) .

Obviously, the pharmacokinetic profiles can be arbitrarily altered, which allows to 372 assess the prophylactic efficacy of any regimen S, e.g. with regards to the drugs taken, 373 their dose, the administration frequency and the timing of drug intake, as outlined Another interesting application of the proposed methods is to assess the impact of the 378 exposure on the prophylactic efficacy, e.g. to assess the sensitivity of ϕ(Y t , S t0 ) with 379 regards to Y t . We have shown previously by simulations [23] EXTRANDE was run 10 000 times for each condition. The error bars denote the 95% confidence bounds for the ensemble estimate, computed using the Greenwood's formula [42] . environment). Also, in [24] , we used stochastic simulation to assess prophylactic efficacy 382 after multiple viral challenges. Here, we demonstrate how the proposed method can be 383 used to address these questions.

Multiple Challenges. Multiple viral challenges can be computed straight-forward 385 as exemplified in the Methods section. In Table 3 we show the estimated prophylactic 386 efficacy for different PrEP regimen (either 3 or 7 doses of 2 or 50mg DTG started at 387 t 0 = 0) with multiple challenges to a single virus particle, computed using both PGS 388 and EXTRANDE. Foremost, as a sanity check, we can see that both methods yield 389 congruent results for all tested conditions. We can also see that higher dose, as well as a 390 longer time course (seven vs. three days) of DTG dosing improves the prophylactic 391 efficacy, even if more viral challenges occur during the short-course prophylaxis. Also, 392 we observe a interesting interplay between the number of exposures and their timing:

For example, if two exposures occur at 1 and 24h after the first dose of DTG vs. three 394 exposures at 1, 24 and 72h after DTG initiation, we see a decrease in efficacy. However, 395 when we compare two exposures occur at 1 and 72h after the first dose of DTG vs. 

where {t i }, i = 1, . . . , n denotes a set of n viral exposures. .87 2 or 50mg oral DTG was ingested for 3 and 7 days respectively starting at t 0 = 0, and 2-4 viral exposures occurred at the time 'Exposure time' hours after DTG initiation. During each exposure one infectious virus entered a replication-enabling compartment. The corresponding prophylactic efficacy was computed by PGS and EXTRANDE, respectively. For each condition EXTRANDE was run 100 000 times. The 95% confidence bounds of the EXTRANDE estimate was computed using the Greenwoods formula [42] . The probability of infection after multiple viral challenges with-and without drug (P I (Y {ti} , S) and P I (Y {ti} , ∅)) were computed with PGS and are depicted in the last 2 columns. Utilized pharmacokinetic parameters were k a = 2.24h −1 , V p /F bio = 0.73 L, Q/F bio = 0.0082 L/h, CL/F bio = 0.85 L/h and V c /F bio = 17.7 L. Now, if P I (Y {ti} , ∅) increases faster with the number of exposures than P I (Y {ti} , S), 401 a scenario may arise, in which the prophylactic efficacy (= relative risk reduction) may 402 be higher, although more exposures happened. I.e. the contextual information, 'when 403 did the exposure(s) occur relative to the drug dosing' is relevant. For example, if many 404 exposures happened at times of almost full protection, the exposed person would be 405 better off than if only a few exposures happened at times of low protection.

Inoculum size. Fig. 4 shows how the profile of prophylactic efficacy is affected by 407 the number of inoculated viruses. This can be calculated from the solution of the PGS 408 is a straight forward way, akin to eq. (14) (statistical independence assumption). In 409 Fig. 4 , we observe that different inculum sizes lead to an (exponential) scaling of the 410 prophylactic efficacy, and that the efficacy deteriorates, when large numbers of viruses 411 are able to reach a replication-competent compartment.

Long-term prophylactic efficacy 413 Because of its superior computational performance, the PGS can also be applied to 414 estimate prophylactic efficacy over very long time scales for population 415 pharmacokinetics (Pop-PK). I.e., typically pharmacokinetic variability is described by 416 statistical models, such as non-linear mixed effects models (NLME), e.g. in [11] . If the 417 pharmacokinetic characteristics of an individual are not known, a Pop-PK model may 418 still be used to accurately capture likely pharmacokinetic profiles in an individual, given 419 a dosing history. The PGS would then allow to predict the profile of prophylactic 420 protection if the individual was exposed to virus at any time during the observation 421 horizon. Note that this type of analysis is usually not feasible with stochastic methods, 422 due to computational demands (for each time point in the profile, several thousand 423 stochastic simulations would be required). (14)). The solutions are plugged into eq (12).

In Fig. 5 , we show the estimated long-term efficacy profile for a chronic, 6-month Using the approaches outlined in the Methods section, it is also possible to compute 438 when the actual extinction event happens after exposure. This is highly useful in 439 determining how long a prophylaxis on-demand should be given. 440 Fig. 6 shows the cumulative probability of extinction, as well as the density function 441 of the extinction event, computed using the PGS for a 3days 50mg DTG regimen that 442 was initiated at t 0 = 0, coinciding with viral exposure. In these simulations, akin to the 443 last example, we sample virtual individuals from the Pop-PK model. Table 2 of [11] . 50 mg dose of DTG / day was ingested in this six-month-long regimen with adherence level of 0.75, 0.5, 0.33 and 0.25. The red line depicts the median predicted prophylactic efficacy, whereas the dark-and light grey areas present the quartile range and the 2.5% − 97.5% range respectively. The prophylactic efficacy was computed for Y 0 = [1, 0, 0] T .

that the cumulative probability of viral extinction is much lower after exposure to 20-448 compared to one virus (panel A vs. C). Moreover, we can see that, after exposure to a 449 single virus, extinction most likely occurs shortly after exposure, e.g. within 1-2 days. 450 In contrast, when 20 viruses are inoculated, extinction is most likely happening at day 4 451 after exposure, and that it is still likely that extinction may occur up to 10 days after 452 exposure when a 3days 50mg DTG prophylaxis is applied. Moreover, extinction is less 453 likely to happen: After exposure to 20 viruses, extinction occurs in 10 days with about 454 75% probability (median), compared to 98% after exposure to a single virus.

In other words, our modelling highlights that the prophylactic efficacy depends on 456 the magnitude of exposure. Moreover, the duration to eliminate the virus is prolonged 457 when more virus becomes inoculated. Essentially, this suggests that large inocula, which 458 may occur after blood transfusions, needle stick exposures, or tissue rupture during 459 sexual contact may require longer duration of prophylaxis to prevent infection. Table 2 of [11] . 50 mg dose of DTG / day was ingested for three days, first dose was taken at t 0 = 0, coinciding with viral exposure. A: cumulative extinction probability for one initial virus. B: probability density function of extinction for one initial virus. C: cumulative extinction probability for 20 initial viruses. D: probability density function of extinction for 20 initial viruses. The red and green lines depict the respective median values, whereas the dark-and light grey areas present the quartile range and 2.5% − 97.5% confidence range, taking inter-individual pharmacokinetic differences into account.

The prophylactic efficacy of novel drug candidates against HIV is determined by the 462 complex interplay of enzymatic, cellular, viral, immunological, pharmacological, as well 463 as behavioural factors [18] . Some of these factors can be described in experimental 464 surrogate systems [43] . However, their complex interplay, which determines clinical 465 efficacy, can usually not be fully described using in vitro or ex vivo experiments.

Moreover, animal models for HIV prophylaxis are suitable for proof-of-concept studies, 467 but may still be confounded by inter-species differences, as well as differences in the 468 viruses used [44] . Lastly, while clinical studies of HIV prophylaxis are useful to assess 469 the relevant efficacy endpoint, they do not allow to disentangle the complex interplay 470 between the aforementioned factors, because of inherent limitations in the study design, 471 sample sizes and the inability to measure the joint interplay of parameters that 472 determine clinical efficacy. Therefore, it remains a formidable challenge to identify 473 factors that alter prophylactic efficacy, or parameters that can be improved by the 474 development of novel drugs or drug formulations for HIV prophylaxis.

Mathematical models [11, 12, 21-24, 28, 45-47] have become an essential tool to 476 complement our knowledge about prophylactic efficacy of antiviral compounds, as they 477 are able to put the different parameters in context and test their relevance for 478 determining prophylactic efficacy. Stochastic simulation methods are currently the gold 479 standard for estimating prophylactic efficacy from these models [11, 12, 21-24, 28, 46, 47] infeasible. In particular, the scope of sensitivity analysis with regards to aforementioned 492 factors in integrated, multiscale-models is usually limited. In this work, we introduce 493 three low-dimensional approaches to estimate the prophylactic efficacy in considerably 494 less time, in a single run. We envision that these approaches can greatly expand the 495 scope of analysis with regards to estimating prophylactic efficacy, by allowing to analyse 496 the long-term effect of prophylaxis, as well as performing sensitivity analysis.

Stochastic simulation methods sample trajectories of the whole system, where any 498 state may arise during simulation. However, in the context of prophylaxis, one is only 499 interested in the probabilities of extinction (and its complement, infection). Therefore, 500 for each state, only those parts that contribute to the extinction event need to be 501 considered. Because the probability of extinction for an arbitrary state can be expressed 502 with the extinction probabilities of the respective unit vectors (eq (14) ; statistical 503 independence), only extinction probabilities for unit vectors need to be computed. This 504 is the main idea behind the three proposed low-dimensional Ansatz functions.

The first method (Next Transition Method (NTM)) is based on the embedded 506 Markov chain described in [11] . The method was inspired by the idea that the For both NTM and CTSM, ∆t must be determined beforehand (see S2 Text and S3 524 Text). In CTSM, only the next time step ∆t is considered, and no look-ahead horizons 525 is needed, which makes the method more efficient than NTM (see Table 2 ). Compared 526 to NTM, the implementation of CTSM is also simpler as only one time step must be 527 considered in each iteration.

Lastly, the Probability Generating System (PGS), eq. (27) can easily be derived 529 from the CTSM by replacing the constant time step ∆t by an infinitesimally small step 530 dt. The method is therefore based on a continuous-time Markov process. Because of the 531 time continuity, the explicit approximations in NTM and CTSM are not necessary in 532 the PGS. In our implementation of the method, we solved the pharmacokinetics 533 beforehand and then wrapped the values of a 5 into a function that can be called directly 534 from within the PGS's ODEs, which are solved backwards in time. It is notable that a 535 backward ODE solver must be used in the implementation, and the use and 536 configuration of different ODE solvers will have an impact on the accuracy and efficacy 537 of this method. However, since modern ODE-solvers use adaptive step sizes, less 538 computations may be needed to ensure accurate results, in comparison to a constant 539 step size method (like NTM or CTSM), Table 2 .

The set of ordinary differential equations (eq. (27)) derived for the PGS is related to 541 the Kolmogorov backward equations [48] , which was used in [22] . The major 542 improvement of our work is to combine this Ansatz with the PK-PD profile of the 543 prophylaxis (eq. (10)) so that the prophylactic efficacy can be computed with arbitrary 544 prophylactic dosing schedules.

While the PGS is directly related to the CTSM, we show in Supplementary Text S6, 546 how to derive PGS from the NTM. Hence, we demonstrated that the three proposed 547 methods describe the same process, using different formalisms and approximations.

In Figure 3 , we also compared the methods head-to-head to demonstrate the 549 equivalence of the obtained results. Figure 3 also shows results of stochastic simulations 550 with EXTRANDE, which delivers consistent, but less accurate results. Likewise, 551 Table 3 shows the consistency of prediction with PGS and EXTRANDE, regarding the 552 prophylactic efficacy for different DTG regimens with multiple viral exposures.

Using the proposed methods, we can also perform analyses that are computationally 554 infeasible with stochastic simulations. As shown in Figure 5 , the long-term prophylactic 555 efficacy profiles were computed using PGS with four different values of adherence and a 556 virtual patient cohort of 1000 individuals. This type of analysis allows to quantify 557 sensitivity with regards to adherence and inter-individual pharmacokinetic variability. 558 The analysis showed that DTG can protect highly adherent individuals from acquiring 559 HIV infection and that inter-individual differences are most strongly affecting 560 prophylaxis at times of inconsistent use of the prophylaxis. Moreover, when several 561 consecutive pills are missed, prophylactic efficacy may drop below 50%. Interestingly, 562 the long-term prophylactic efficacy computation took less than 2 seconds for one virtual 563 patient. To compute the corresponding profile with EXTRANDE, for example if an 564 efficacy estimate is to be computed for every hour using 5000 simulations, a total of 565 24 × 365 × 5000 ≈ 44 million simulations for a single adherence level would need to be 566 conducted. Besides computational time, power consumption (and possible carbon 567 imprint) could therefore be considerably reduced using the proposed methods.

Another possible application of the proposed methods is the possibility to estimate 569 the time of the extinction event, Fig. 6 . As a showcase of a sensitivity analysis, we 570 estimated, for a 3-days 50mg DTG regimen, the probability density function of the 571 extinction event, when a single, versus 20 viruses were initially reaching a 572 replication-competent physiological compartment. The analysis showed that the time to 573 July 6, 2021 21/27 viral extinction is increased for larger inoculum sizes (more viruses). This analysis thus 574 highlights the complex interplay between viral exposure and prophylaxis that can be 575 analysed with the proposed methods and be used to optimize HIV prophylaxis. With 576 regards to data, interestingly, in vaginal SHIV viral challenge models, which are typically 577 conducted with large inoculum sizes, late viral breakthrough has been observed [49, 50] . 578 The presented methods have been derived for the model depicted in Fig. 1 and need 579 to be adjusted if other viral dynamics models were used. In Supplementary Text S5, we 580 derive the three methods for an extended viral dynamics model that additionally 581 considers long-lived cells (e.g. macrophages) and infected T cells, which may turn 582 dormant, e.g. become latently infected. It is well established that these latent reservoirs 583 are a major obstacle to the elimination of HIV during therapy [51] . While these 584 reservoirs are established early in infection, it is unclear whether they alter prophylactic 585 efficacy. To test this hypothesis, we used the proposed methods for the extended viral 586 dynamic model (Supplementary Text S5) . When comparing the results with those from 587 the simpler model, we however found that the impact of the reservoirs on prophylactic 588 efficacy was negligible.

In summary, we propose three novel methods that can estimate the efficacy of 590 arbitrary prophylactic regimen and viral exposures within seconds. The three methods 591 allow to integrate individual PK/PD profiles and viral dynamics into a single framework 592 and they are more exact than state-of-art hybrid stochastic simulation schemes, like 593 EXTRANDE. We envision that the new methods can be applied in many circumstances, 594 in which the stochastic simulation is computationally infeasible, such as parameter 595 sensitivity analysis or long-term efficacy estimation. To this end, the proposed methods 596 may even be suitable as part of an App, which may help PrEP users to monitor and plan 597 their PrEP regimen. Moreover, the general schemes may be adapted to study related 598 biomedical questions, like prophylactic efficacy in other pathogens or vaccine efficacy. 

S2 Text The supplementary text contains a complete pseudo-code and 603 the implementation details for the Next Transition Method (NTM)

S6 Text The supplementary text derived the Probability Generating 612

System (PGS) from the Next Transition Method (NTM)

Acknowledgments 614

acknowledge funding from the German Ministry for Science and 615

The funders had no role in designing the 616

Origins of HIV and the AIDS pandemic. Cold Spring Harbor Perspectives in Medicine

The Risks and Benefits of Providing HIV Services during the COVID-19 Pandemic

Investigational Antiretroviral Drugs: What is Coming Down the Pipeline

HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals

Eradicating HIV-1 infection: seeking to clear a persistent pathogen

Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic

Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? The Lancet

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes

The Utility of Efavirenz-based Prophylaxis Against HIV Infection. A Systems Pharmacological Analysis

Long-acting drugs and formulations for the treatment and prevention of HIV infection

Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline

Sexual transmission of HIV

Statistical issues in trials of preexposure prophylaxis

HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise

Bottlenecks in HIV-1 transmission: insights from the study of founder viruses

Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action

Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis

Stochastic analysis of pre-and postexposure prophylaxis against HIV infection

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection

Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1

working group on SARS-CoV-2 Diagnostics at RKI. COVIDStrategyCalculator: A software to assess testing-and quarantine strategies for incoming travelers, contact person management and de-isolation

Drug-class specific impact of antivirals on the reproductive capacity of HIV

HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs

The probability of HIV infection in a new host and its reduction with microbicides

Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies

Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection

Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle

Viral dynamics in human immunodeficiency virus type 1 infection

Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir

Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro

A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Mechanistic framework predicts drug-class specific utility of antiretrovirals for HIV prophylaxis

Stochastic modelling for systems biology

Stochastic simulation of biomolecular networks in dynamic environments

A report on the natural duration of cancer. A Report on the Natural Duration of Cancer

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

Animal models for HIV/AIDS research

A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine

A model of HIV drug resistance driven by heterogeneities in host immunity and adherence patterns

Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes

Über die analytischen Methoden in der Wahrscheinlichkeitsrechnung

A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge

Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission

HIV reservoirs as obstacles and opportunities for an HIV cure

The authors declare no competing interests.